Taken together, these studies supported the finding that therapeutic targeting of the EGFR/FOXC1/NFκB pathway and PI3K/AKT/mTOR in BLBC, PI3K/AKT/HIF-1α/FOXC1 axis in HCC and MST1R/PI3K/AKT in cervical cancers, melanoma and pancreatic cancers, may provide effective modalities for treatment. This evidence concerns the gene FOXC1 and hepatocellular carcinoma.